This inventor holds 3 USPTO granted patents and 5 published patent applications. Top assignee: Biotheus Inc.. Active years: 2025-2026.
Company Filing History:
Years Active: 2025-2026
Title: The Innovative Contributions of Andy Tsun
Introduction
Andy Tsun is a prominent inventor based in Guangdong, China. He has made significant strides in the field of biomedicine, particularly with his innovative antibody technologies. With a total of 3 patents to his name, Tsun is recognized for his contributions to cancer treatment and immune system activation.
Latest Patents
Tsun's latest patents include the "Anti-PD-L1 single-domain antibody and derivatives and use thereof." This invention provides a complementary determining region (CDR) of a VHH chain of an anti-PD-L1 single-domain antibody, which includes specific amino acid sequences that enhance its efficacy. Another notable patent is the "Anti-VEGF-anti-PD-L1 bispecific antibody, pharmaceutical composition of same, and uses thereof." This bispecific antibody is designed to target both VEGF and PD-L1, thereby activating the immune system while simultaneously blocking tumor angiogenesis, offering promising antitumor prospects.
Career Highlights
Andy Tsun is currently associated with Biotheus Inc., where he continues to develop groundbreaking biopharmaceuticals. His work focuses on creating innovative solutions that address critical health challenges, particularly in oncology.
Collaborations
Tsun collaborates with notable colleagues such as Zhijun Yuan and Weifeng Huang, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Andy Tsun's contributions to the field of biomedicine through his patents and collaborative efforts highlight his role as a key innovator in cancer treatment. His work continues to pave the way for advancements in therapeutic strategies.